By Veyvora Research · Updated September 2026
PT-141 (Bremelanotide) Research: MC4 Receptor Context
Overview
PT-141, the research name for bremelanotide, is a synthetic melanocortin-receptor agonist studied in in-vitro laboratory settings for its activity at MC1R, MC3R, and MC4R, with MC4 receptor signalling forming the primary mechanistic frame in the published literature. Research-grade material is a laboratory presentation of the compound, and receptor-level findings describe receptor-level activity.
Bremelanotide belongs to the α-MSH (alpha-melanocyte-stimulating hormone)/Melanotan II peptide family and is characterised by its receptor profile rather than by any single biological outcome. The MC4 receptor context matters because MC4R-linked pathways are central to neurobiological and endocrine signalling models, making PT-141 a defined tool compound for probing those systems in assay conditions. A result obtained in one cell line, species, or concentration range applies to that system; a different experimental system or a different batch is characterised on its own terms, with the batch’s analytical documentation as the starting point.
This article covers how PT-141’s receptor binding profile defines its research identity, what the in-vitro, preclinical and clinical evidence each establishes and where those tiers diverge, and what analytical checks a research-grade batch needs before it goes into an assay.
Key Takeaways
- PT-141 (bremelanotide) is a chemically defined synthetic peptide; its research identity is established by peptide sequence and molecular weight, not by trade name.
- MC4R is the receptor subtype most consistently associated with PT-141 in the published pharmacological literature, though binding activity at MC1R and MC3R is also documented.
- Evidence from in-vitro assays, preclinical rodent models, and clinical pharmaceutical trials represents three distinct tiers; each tier answers its own question.
- Bremelanotide is also the active substance of the registered medicine Vyleesi (US FDA, 2019); research-grade material is a separate laboratory presentation of the same molecule.
- Batch-level analytical documentation (HPLC purity, mass spectrometry confirmation and endotoxin data) is the verification that precedes any assay.
Definition and Identity
PT-141, also called bremelanotide, is a synthetic cyclic heptapeptide and melanocortin-receptor agonist derived from the α-MSH family, studied in in-vitro settings for its activity at MC1R, MC3R, and MC4R, with MC4 receptor signalling forming the primary mechanistic frame in the published pharmacological literature.
Bremelanotide is classified as a melanocortin ligand, not a generic peptide label. Its research identity is defined by its receptor binding profile: MC4R is the subtype most consistently associated with central neurobiological signalling models in which PT-141 serves as a tool compound. Researchers sourcing PT-141 for in-vitro work should treat the names “PT-141” and “bremelanotide” as synonymous identifiers for the same chemically defined entity, confirmed by peptide sequence and molecular weight rather than by trade name alone.
The PT-141 20 mg Bremelanotide Pen product page provides the specific material and batch documentation relevant to sourcing decisions. Purity and structural identity against published bremelanotide are established by batch-level analytical documentation; understanding what HPLC purity does and does not prove explains how to read the chromatographic data supplied with a batch.
Mechanism and Research Context
PT-141 (bremelanotide) acts as a functional agonist at melanocortin receptors, with MC4R representing the primary pharmacological target in central neurobiological research models. Binding to MC4R activates adenylyl cyclase via Gs-protein coupling, elevating intracellular cyclic AMP (cAMP) concentrations and initiating downstream signalling cascades in neural and endocrine cell systems, a cause-and-effect relationship that makes MC4R the central reference point for interpreting bremelanotide’s activity in assay data.
MC4R Signalling as the Research Frame
In in-vitro assay systems, bremelanotide serves as a tool compound to probe MC4R-linked cAMP responses, receptor occupancy, and pathway kinetics. The receptor’s expression in hypothalamic and limbic regions makes it a target of interest in neurobiological models examining energy regulation and autonomic signalling. Any interpretation of results depends strictly on the cell line, species origin, receptor expression level, and concentration range used in the specific assay; mechanistic findings from one overexpressing cell-line model are specific to that system.
PT-141 also shows binding activity at MC1R and MC3R, but the published pharmacological literature most consistently frames bremelanotide within MC4R-centred discussion. Receptor selectivity is assay-dependent: the relative affinity profile reported in one study reflects that study’s conditions.
Because receptor activity is concentration- and purity-sensitive, confirming the analytical identity of the material used matters before any mechanistic interpretation is attempted. Researchers can verify a batch against its CoA to confirm that the peptide sequence and purity data align with the published bremelanotide reference before designing assays. Consulting storage and stability guidance for research peptides is relevant at this stage, since degradation can alter the receptor-binding profile of a peptide and confound mechanistic results.
What the Evidence Shows
The published evidence positions bremelanotide as a characterised melanocortin agonist with documented receptor-level activity, but the strength and scope of that evidence varies considerably across experimental tiers.
In-Vitro and Receptor-Level Evidence
At the receptor level, the most consistent body of work concerns MC4R binding and the downstream cAMP signalling cascade. Cell-based assays using heterologous expression systems, for example, HEK293 cells transfected with human MC4R, have demonstrated that bremelanotide acts as a functional agonist at MC4R, producing measurable intracellular responses under controlled conditions. This tier is the most reproducible because the key variables (receptor density, cell line, ligand concentration) can be defined precisely. Researchers sourcing PT-141 for in-vitro work should consult the peptide research glossary for definitions of assay-specific terms such as EC₅₀ (the concentration producing half-maximal effect), receptor occupancy, and functional selectivity before interpreting published binding data.
Preclinical Evidence
Preclinical studies, predominantly in rodent models, have examined bremelanotide in the context of melanocortin-linked autonomic and neuroendocrine pathways. Results from this tier are model-specific: the species, receptor expression profile, and route of administration all affect the observed outcome, which is why each model’s findings are reported with its species and tissue preparation.
Clinical Evidence
The clinical evidence base sits at a separate tier. Bremelanotide received US Food and Drug Administration (FDA) approval in 2019 under the brand name Vyleesi for a specific indication in premenopausal adults; that approval applies to the registered pharmaceutical formulation, and research-grade material is a separate laboratory presentation of the same molecule. For researchers evaluating PT-141 as a tool compound, the clinical literature is contextual background, and what a given research batch produces in a specific assay is established by that assay.
State of the Evidence
Three distinct evidence tiers apply to bremelanotide research: in-vitro receptor assays, preclinical animal models, and clinical pharmaceutical data. Each tier is defined by its own variables (receptor density, cell background, ligand concentration, species and assay endpoint), so each published finding is model-specific and read within its tier.
Reading Across Tiers
The bremelanotide literature often presents receptor pharmacology and clinical discussion together; keeping the two apart separates what the molecule does in a controlled assay from what the registered formulation does in a human trial. The 2019 US FDA approval of Vyleesi applies to a specific medicinal product under defined manufacturing standards, and a research-grade batch is documented by its own certificate. Reviewing what HPLC purity does and does not prove is the step for reading the chromatographic data supplied with a research batch.
Batch-Level Documentation
General literature describes bremelanotide as a molecule; the identity, sequence confirmation and chromatographic profile of a given batch are reported on its certificate. Researchers verify a batch against its CoA before committing it to an assay, since batch-number matching connects the analytical result to the physical material received.
Comparison with Related Compounds
PT-141 (bremelanotide) is most usefully compared with Melanotan II, because both are synthetic melanocortin-pathway peptides and PT-141 is generally treated as a derivative within that family. The practical distinction is receptor emphasis: PT-141 is presented in the literature as MC4-focused, whereas Melanotan II is discussed as a broader melanocortin agonist prototype with activity spanning MC1R through to MC4R, including MC1R-mediated pigmentation pathways.
PT-141 versus Melanotan II
| Criterion | PT-141 (Bremelanotide) | Melanotan II |
|---|---|---|
| Primary receptor framing | MC4R-centred | Broader MC1R–MC4R activity |
| Research identity | Bremelanotide; chemically defined synthetic peptide | Synthetic α-MSH analogue |
| Regulatory context | Active substance of the registered medicine Vyleesi (US FDA, 2019); research-grade material is a separate presentation | Research compound |
| Typical research use | MC4R signalling and central pathway studies | Melanocortin receptor pharmacology broadly |
PT-141 research material and the registered medicine containing bremelanotide are separate presentations of the same active substance, each documented in its own way: the medicine by its regulatory dossier, the research batch by its certificate of analysis. Consult the peptide research glossary for definitions of terms such as agonist, receptor selectivity, and assay that underpin this comparison.
Material Identity and Analytical Context
For PT-141 research use, material identity is established by analytical documentation, not by product name alone. A batch of PT-141 (bremelanotide) should be verified against its peptide sequence, stated molecular weight, chromatographic purity figure, and any accompanying mass spectrometry or HPLC (high-performance liquid chromatography) data before it is committed to an assay. The batch-level documents are what establish purity and structural identity against published bremelanotide.
What Each Analytical Method Reports
HPLC purity data reports the proportion of the target compound relative to detectable impurities under the specific chromatographic conditions used. Mass spectrometry confirms molecular mass and, where fragmentation data is included, sequence identity. Biological activity and receptor selectivity are established in the assay itself, since experimental outcomes depend on the cell line, buffer conditions and concentration range used.
Veyvora states that each research-peptide batch is checked by two independent laboratories using HPLC, mass spectrometry, and endotoxin assay, with a published batch-level certificate of analysis (CoA). Request and review that certificate before use. For a fuller account of what chromatographic purity data reports, see what HPLC purity does and does not prove.
Research Use
PT-141 (bremelanotide) is supplied as a research peptide for in-vitro laboratory work: MC4R signalling assays, receptor-occupancy and pathway-kinetics studies. Not for human or veterinary use. Research-grade material is manufactured and quality-controlled for that laboratory use, and is a separate presentation from the registered medicine that shares its active substance.
Researchers sourcing PT-141 for in-vitro assays confirm three things before committing a batch to an experiment: that the supplier provides a batch-specific CoA; that the certificate includes HPLC purity, mass spectrometry confirmation, and endotoxin data; and that the batch number on the certificate matches the vial received. To verify a batch against its CoA, follow the procedural steps on that page before any assay begins.
Once material identity is confirmed, correct storage becomes the next critical variable, because peptide degradation between receipt and use can invalidate results independently of initial purity. Review storage and stability guidance for research peptides for the site’s current 2–8 °C handling requirements before logging the batch into your inventory.
To source the specific material discussed throughout this article, visit the PT-141 20 mg Bremelanotide Pen product page, where current batch documentation and pricing are listed.
